With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

The partnership will focus on advancing RGX-121 as a treatment for mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for treating mucopolysaccharidosis I (MPS I), also ...

Lucky Girl Syndrome centers on a simple yet powerful idea: by repeatedly telling yourself that you’re lucky and everything works out for you, you’ll attract positive outcomes. Think of it as a hybrid ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

Hunter syndrome affects over 2,000 individuals, primarily males, in commercially accessible regions. With analysts maintaining a Strong Buy consensus and the company maintaining a healthy liquidity ...

While this period may feel uncertain as old systems fade, it’s a powerful window for transformation and manifestation. This conjunction signals the start of a three-year cycle, promising significant ...

Storyline: When his abusive father’s actions cause him to escape home, Kraven finds haven in a sanctuary and turns into a hunter only to know that he’s being hunted As a fan of Hollywood films ...